<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;TSC1&lt;/i&gt; and &lt;i&gt;TSC2&lt;/i&gt; (tuberous sclerosis complex genes)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>TSC1</i> and <i>TSC2</i> (tuberous sclerosis complex genes)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>TSC1</i> and <i>TSC2</i> (tuberous sclerosis complex genes)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephanie Randle, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laura S Farach, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2860079319"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>TSC1</em> and <em>TSC2</em> are disease genes for tuberous sclerosis complex (TSC), a neurocutaneous disorder in which hamartomas and other benign tumors form in many organs including brain, skin, and kidneys. Neurological manifestations including autism, intellectual disability, and epilepsy are also common. (See <a class="local">'Overview of tuberous sclerosis complex'</a> below.)</p><p>This monograph summarizes the interpretation of genetic testing of <em>TSC1</em> and <em>TSC2</em>. Evaluation and management of TSC are discussed separately [<a href="#rid1">1</a>]. (See <a class="local">'Resources'</a> below.)</p><p class="headingAnchor" id="H3911719040"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>Considerations are summarized in the table  (<a class="graphic graphic_table graphicRef122437" href="/d/graphic/122437.html" rel="external">table 1</a>). These include the importance of viewing the actual report, checking qualifications of the testing laboratory, determining which gene(s) and which variants were tested, and reviewing the testing method. Considerations specific to <em>TSC1</em> and <em>TSC2</em> are noted below. (See <a class="local">'TSC1 and TSC2 genes'</a> below.)</p><p>Testing for clinical care should be performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (or other nationally certified laboratory). If the results would impact clinical decision-making and the original testing was not from a CLIA-certified laboratory, it should be repeated. This applies both to positive results and to negative results in an individual considered to be at risk.</p><p>Terms that may be used in the report are summarized in the table  (<a class="graphic graphic_table graphicRef122429" href="/d/graphic/122429.html" rel="external">table 2</a>). An extensive glossary is also available. (See  <a class="medical medical_review" href="/d/html/2898.html" rel="external">"Genetics: Glossary of terms"</a>.)</p><p class="headingAnchor" id="H794947427"><span class="h2"><i>TSC1 </i>and <i>TSC2 </i>genes</span><span class="headingEndMark"> — </span><em>TSC1</em> and <em>TSC2</em> are the main disease genes responsible for TSC. They act as tumor suppressors. Individuals with TSC are heterozygous for a pathogenic variant on one allele of the affected gene, and a second hit (somatic loss of the normal allele) results in complete loss of protein function and eventually tumor development.</p><p>The mechanism of hamartoma formation is thought to involve deregulated entry into the cell cycle caused by increased activity of the mTOR protein kinase. This occurs due to increased activity of the mTORC1 complex, which controls protein synthesis, the G1-S cell cycle transition, and cell proliferation in response to nutrient availability and redox changes. </p><p class="bulletIndent1"><span class="glyph">●</span><em>TSC2</em> encodes tuberin, a GTPase-activating protein that regulates the mTORC1 complex.</p><p class="bulletIndent1"><span class="glyph">●</span><em>TSC1</em> encodes hamartin, a protein chaperone that stabilizes tuberin and prevents its degradation.</p><p></p><p>Increased activity of mTOR leads to deregulated entry into the cell cycle. Inhibition of mTOR with mTOR inhibitors such as rapamycin can treat many of the manifestations of TSC. </p><p>Approximately one-third of TSC cases are inherited and two-thirds (approximately 70 percent) arise de novo (see <a class="local">'Inheritance'</a> below). Inherited cases are divided equally between <em>TSC1 </em>and <em>TSC2</em> variants; for de novo cases, four-fifths are due to <em>TSC2 </em>variants. Thus, overall, approximately 30 percent of individuals with TSC have a pathogenic variant in <em>TSC1</em> and 70 percent have a pathogenic variant in <em>TSC2</em>. <em>TSC2</em> variants are generally thought to be associated with more severe disease, but this is not always the case.</p><p>Implications for <em>TSC1</em> and <em>TSC2</em> genetic testing include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis in an individual not previously suspected of having TSC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Confirmation of suspected TSC in a person meeting one major or two minor criteria (especially helpful prenatally [fetus with rhabdomyoma] and in infants and young children too young to fulfill criteria).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased ease of evaluating parents and siblings using testing for a known familial variant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preconception counseling and planning, which may include preimplantation genetic testing (PGT) or chorionic villus sampling or amniocentesis during pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possibility of diagnosing combined TSC and polycystic kidney disease (PKD). The <em>TSC2</em> gene is physically adjacent to the PKD gene <em>PKD1</em>, and some individuals have a contiguous deletion including both genes. (See  <a class="medical medical_review" href="/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex", section on 'TSC2/PKD1 contiguous gene syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possibility of obtaining prognostic information via genotype-phenotype correlations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possibility of identifying somatic or gonadal mosaicism (germline gene variant in some tissues but not others). (See  <a class="medical medical_review" href="/d/html/2897.html" rel="external">"Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Mosaicism'</a>.)</p><p></p><p class="headingAnchor" id="H101618216"><span class="h1">OVERVIEW OF TUBEROUS SCLEROSIS COMPLEX</span></p><p class="headingAnchor" id="H4146292949"><span class="h2">Inheritance</span><span class="headingEndMark"> — </span>Inheritance of TSC is autosomal dominant and can be inherited from a parent. However, two-thirds (approximately 70 percent) of individuals with TSC appear to have a de novo mutation. (See <a class="local">'TSC1 and TSC2 genes'</a> above.)</p><p>Penetrance is complete (all individuals with a pathogenic variant in <em>TSC1</em> or <em>TSC2</em> will manifest features of TSC), but expressivity is highly variable; the specific manifestations, including disease severity and affected organs, can differ widely, even in individuals from the same family with the same pathogenic variant. These concepts and mechanisms are explained separately. (See  <a class="medical medical_review" href="/d/html/2897.html" rel="external">"Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Penetrance and expressivity'</a>.)</p><p>The incidence of TSC at birth is approximately 1 in 6000 to 1 in 10,000; prevalence declines with age due to early mortality in severely affected individuals [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H659507928"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Different organ manifestations predominate at different stages of life, which has implications for the timing of surveillance and interventions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart</strong> – The most common presenting feature in infancy is intracardiac rhabdomyoma (60 percent) [<a href="#rid3">3</a>]. This may be diagnosed prenatally by fetal ultrasound, which may diagnose 35 percent of cases prenatally. Cardiac rhabdomyomas tend to regress over time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic</strong> – Seizures are the presenting sign in up to 15 percent of infants [<a href="#rid3">3</a>]. Seizure activity may present as infantile spasms, focal seizures, or generalized seizures. Seizure prevalence is as high as 90 percent. (See  <a class="medical medical_review" href="/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>.)</p><p></p><p class="bulletIndent1">Over 90 percent of infants will have structural brain changes including cortical tubers and subependymal nodules (SEN). These lesions are most likely to develop during active brain remodeling. SEN will grow to become subependymal giant cell astrocytomas (SEGAs; also called subependymal giant cell tumors [SGCTs]) in approximately 25 percent of individuals. SEGAs are rarely present in infancy [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1">Other neurologic manifestations include developmental delay, learning difficulty, autism, and behavioral problems.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney</strong> – Tumors in the kidney (hamartomas, angiomyolipomas [also benign]) tend to grow with age. They can compress normal tissues and/or bleed extensively, which can cause kidney failure. Kidney cysts may also be noted, and some individuals with variants in <em>TSC2</em> can have polycystic kidney disease (PKD). (See <a class="local">'TSC1 and TSC2 genes'</a> above and  <a class="medical medical_review" href="/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin</strong> – Skin lesions include ash leaf spots or hypomelanotic macules (which can be seen anywhere on the body, including in the hair), angiofibromas (typically on the face), fibrous plaques (typically on the forehead), shagreen patches (typically on the lower back), and ungual fibromas (in the nail bed). Hypomelanotic macules are the presenting feature in approximately 40 percent of patients and may require a Wood's lamp for identification [<a href="#rid3">3</a>]. Other dermatologic findings may develop or progress over time. (See  <a class="medical medical_review" href="/d/html/3004.html" rel="external">"The genodermatoses: An overview", section on 'Tuberous sclerosis complex'</a>.)</p><p></p><p>Some individuals are diagnosed later in adulthood with minimal clinical findings, often after the birth of an affected child to two seemingly unaffected parents.</p><p class="headingAnchor" id="H2599826876"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Diagnostic criteria  (<a class="graphic graphic_table graphicRef66759" href="/d/graphic/66759.html" rel="external">table 3</a>) were updated in a 2021 consensus conference [<a href="#rid4">4</a>].</p><p>Individuals with possible TSC based on suggestive clinical findings and/or an affected first-degree relative should be evaluated as early as possible. Early diagnosis may facilitate interventions to reduce complications, especially for young children who are at the greatest risk for seizures. Those with an affected first-degree relative require an evaluation even if clinical manifestations are not obvious. An approach to testing first-degree relatives is summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef131926" href="/d/graphic/131926.html" rel="external">algorithm 1</a>). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Known familial variant</strong> – If a familial pathogenic or likely pathogenic variant is known, testing can be restricted to that variant.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Family members who test positive for the variant have TSC and should be evaluated as soon as possible  (<a class="graphic graphic_table graphicRef128085" href="/d/graphic/128085.html" rel="external">table 4</a>). Infants under five or six months may be able to undergo brain magnetic resonance imaging (MRI) without general anesthesia; older children may require anesthesia for MRI.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Family members who test negative for the variant can be reassured that they do not have TSC, provided testing was accurate (see <a class="local">'How to read the report'</a> above). This allows the individual to avoid the costs and burdens of extensive evaluations. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial variant unknown</strong> – If a familial variant is <strong>not</strong> known, genetic testing and clinical evaluations  (<a class="graphic graphic_table graphicRef128085" href="/d/graphic/128085.html" rel="external">table 4</a>) can be performed. Either may confirm the diagnosis if positive; if both are negative, the diagnosis is excluded. </p><p></p><p class="bulletIndent1">Genetic testing can be used to confirm the diagnosis and to assist in testing and counseling of first-degree relatives.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenic variant</strong> – Individuals with a pathogenic or likely pathogenic variant in <em>TSC1</em> or <em>TSC2</em> meet criteria for TSC, provided testing was performed correctly, and they should be evaluated and monitored according to accepted clinical guidelines. This applies regardless of the reason for testing (expected or unexpected finding). (See <a class="local">'Management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VUS</strong> – Individuals with a variant of uncertain significance (VUS) in <em>TSC1</em> or <em>TSC2</em> should be managed based on their clinical history. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Negative result</strong> – Individuals for whom a pathogenic variant is not identified (including those with a benign or likely benign variant) are managed based on their clinical history. If a pathogenic or likely pathogenic familial variant is known and the individual tests negative for that variant, they can be reassured that they are unaffected. If clinical features of TSC are present, the individual should be managed based on the clinical diagnosis; inability to document a disease variant does not affect their management. Consultation with a genetics expert may help determine if further testing could clarify the diagnosis or assist with evaluations of relatives. (See <a class="local">'Resources'</a> below.)</p><p></p><p class="headingAnchor" id="H1827783225"><span class="h2">Management</span><span class="headingEndMark"> — </span>Individuals with TSC should be managed by (or in consultation with) a multidisciplinary team with expertise in TSC.</p><p>The table lists the age to initiate evaluations and surveillance monitoring intervals  (<a class="graphic graphic_table graphicRef128085" href="/d/graphic/128085.html" rel="external">table 4</a>) [<a href="#rid5">5</a>].</p><p>The following illustrates the scope of management implications: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Education</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anticipatory education about infantile spasms and seizures, including how to recognize them and what to do if they occur. (See  <a class="medical medical_review" href="/d/html/6145.html" rel="external">"Infantile epileptic spasms syndrome: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic counseling; testing and counseling of first-degree relatives. (See <a class="local">'Inheritance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Support resources. (See <a class="local">'Resources'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance </strong>(intervals listed in the table  (<a class="graphic graphic_table graphicRef128085" href="/d/graphic/128085.html" rel="external">table 4</a>))</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Examinations </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Checklist for TSC-associated neuropsychiatric disorder (TAND)</p><p class="bulletIndent3"><span class="glyph">-</span>Blood pressure</p><p class="bulletIndent3"><span class="glyph">-</span>Ophthalmologic, dental, and skin examinations</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Imaging</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Brain MRI (non-contrast)</p><p class="bulletIndent3"><span class="glyph">-</span>Ultra low-dose computed tomography (CT) of the lungs in all females 18 years and older and in symptomatic males </p><p class="bulletIndent3"><span class="glyph">-</span>Abdominal MRI</p><p></p><p class="bulletIndent2">Due to the number of repeat scans and unknown long-term effects, contrast agents are avoided unless there is a growing lesion or clinical suspicion for a SEGA. If contrast is used, group 1 agents should be avoided [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other testing</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pulmonary function tests </p><p class="bulletIndent3"><span class="glyph">-</span>Echocardiogram and electrocardiogram</p><p class="bulletIndent3"><span class="glyph">-</span>Electroencephalogram (EEG)</p><p class="bulletIndent3"><span class="glyph">-</span>Assessment of kidney function (determination of glomerular filtration rate [GFR])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interventions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tumors </strong>– mTOR inhibition with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> is used for tumors causing functional impairment, SEGAs &gt;1 cm or causing hydrocephalus, growing kidney tumors, and cardiac tumors causing heart failure. Therapy can cause tumors to regress; typically, it is continued indefinitely. Surgery may be appropriate in selected cases.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seizures</strong> – <a class="drug drug_general" data-topicid="10115" href="/d/drug information/10115.html" rel="external">Vigabatrin</a> is used for infantile spasms, with possible prophylactic use in selected individuals. Seizures are treated with an appropriately chosen antiseizure medication. Interventions for medically refractory epilepsy may include epilepsy surgery, dietary therapy (such as ketogenic diet), vagus nerve stimulation, <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, and/or cannabidiol. Clinical trials are evaluating interventions for seizure prophylaxis (vigabatrin, everolimus); specialist input can address the latest recommendations. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cognitive/behavioral</strong> – Early interventions and services are provided as needed. Seizure prevention is emphasized.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Skin</strong> – Interventions include sun protection, laser therapy or dermabrasion for cosmesis, possibly topical mTOR inhibitor therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac tumors</strong> – These can spontaneously regress and may not require surgical intervention unless they cause symptoms.</p><p></p><p>Specialty centers will be aware of clinical trials that could be appropriate.</p><p class="headingAnchor" id="H3173668491"><span class="h1">RESOURCES</span></p><p class="bulletIndent1"><span class="glyph">●</span>Information in UpToDate</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pathogenesis – (See  <a class="medical medical_review" href="/d/html/142618.html" rel="external">"Tuberous sclerosis complex: Genetics and pathogenesis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Diagnosis – (See  <a class="medical medical_review" href="/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/143210.html" rel="external">"Tuberous sclerosis complex: Evaluation and diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Treatment – (See  <a class="medical medical_review" href="/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Kidney – (See  <a class="medical medical_review" href="/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Skin – (See  <a class="medical medical_review" href="/d/html/3004.html" rel="external">"The genodermatoses: An overview", section on 'Tuberous sclerosis complex'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Lung – (See  <a class="medical medical_review" href="/d/html/4329.html" rel="external">"Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TSC resources</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TSC Alliance (United States) – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.tscalliance.org%2F&amp;token=mvT%2Ffm0DU2zopq8%2B0NghZ2CdwZjgJMb445bhsxSGUNrB%2B5rZUKGMV%2BWX3duc5h8T&amp;TOPIC_ID=131601" target="_blank">tscalliance.org</a></p><p class="bulletIndent2"><span class="glyph">•</span>Tuberous Sclerosis Association (United Kingdom) – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ftuberous-sclerosis.org%2F&amp;token=pW6EGICsOu9D%2Bp81s1dgfSBrwUztZcza2Am33ynG0F9KRRmXgW5m7t395w6T4BXh&amp;TOPIC_ID=131601" target="_blank">tuberous-sclerosis.org</a></p><p class="bulletIndent2"><span class="glyph">•</span>Other societies – (See  <a class="medical medical_society_guidelines" href="/d/html/120578.html" rel="external">"Society guideline links: Tuberous sclerosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>National Institutes of Health (NIH) – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ninds.nih.gov%2Ftuberous-sclerosis-fact-sheet&amp;token=lblfowwGB6QwC91WNuiIfw3PuDqkl6bRypmAhb4%2Bv2bYDomsmDpsBWLNISUBYmDK0Idop0dlNGkdaj5qDNiOxg%3D%3D&amp;TOPIC_ID=131601" target="_blank">Fact sheet</a> for patients</p><p class="bulletIndent2"><span class="glyph">•</span>List of TSC clinics (United States) - <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.tscalliance.org%2Findividuals-families%2Ftsc-clinics%2F&amp;token=PJxPgiHFA3SgR3Ow9vACLmu77FhC9ZU3jx4bH98jDLOkhMVSVvyJ3KKyMA3ZAzBKiV7z0x0Jiv7GOPe6pP%2BTNq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=131601" target="_blank">tscalliance.org/individuals-families/tsc-clinics/</a></p><p class="bulletIndent2"><span class="glyph">•</span>List of TSC organizations around the world – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.tscinternational.org%2Ffind-a-tsc-organization%2F&amp;token=mvT%2Ffm0DU2zopq8%2B0NghZ%2FfzVkLRu57TNXX0wHU%2FFd%2BHYtMj57PsshVMHbZIVS5OzJmOBxYlV%2BDPJTMJs0iE7Q%3D%3D&amp;TOPIC_ID=131601" target="_blank">tscinternational.org/find-a-tsc-organization/</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Locating a genetics professional</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=131601" target="_blank">ACMG</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=131601" target="_blank">NSGC</a>)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Randle SC. Tuberous Sclerosis Complex: A Review. Pediatr Ann 2017; 46:e166.</a></li><li><a class="nounderline abstract_t">Davis PE, Filip-Dhima R, Sideridis G, et al. Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Northrup H, Aronow ME, Bebin EM, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol 2021; 123:50.</a></li><li class="breakAll">https://www.tscinternational.org/wp-content/uploads/2019/01/TSCi-Consensus-Guidelines.pdf (Accessed on May 25, 2021).</li></ol></div><div id="topicVersionRevision">Topic 131601 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28414398" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tuberous Sclerosis Complex: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29101226" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34399110" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
